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Abstract:
Objective: To assess the prevalence of hyperhomocysteinemia in Parkinson’s Disease (PD) and if
this elevated serum level can be used as a predictive biomarker in risk assessment for the
progression of cognitive decline in PD.
Design: Systematic Literature Review
Methods: A literature search was conducted through Google Scholar and Pubmed using phrases
such as, “Parkinson's Disease”, and “homocysteine”, “Parkinson’s progression. Three articles,
measuring serum homocysteine levels and cognitive functioning in PD patients, were selected,
analyzed, and compared to assess for a relationship between homocysteine levels and cognitive
decline in PD.
Results: Elevated homocysteine levels are associated with worse cognitive scores in some
areas of neurocognitive testing in PD patients as compared to those with normal homocysteine
levels.
Conclusion: Though study results do show an inversely proportional relationship between
homocysteine serum levels and cognitive function, the presence of confounding variables
within PD subjects, as well as, the unknown physiologic mechanism of homocysteine and
neurons, makes it difficult to find a causal relationship between elevated homocysteine and
neurocognitive function in PD.
Introduction:
Parkinson's disease (PD), the second most prevalent neurodegenerative condition after
Alzheimer’s disease, is characterized by a progressive loss of motor and cognitive function1. The
precise mechanism of neurodegenerative decline is largely unknown and there are few
laboratory tests to track its progress. The diagnosis and progression of PD is based upon its
distinctive clinical features from the history and neurological exam. Though it is understood
that a deficiency in dopamine and atrophy of the substantia nigra is involved in the disease
process, these pathological pathways are difficult to track until it is too late or without
extensive imaging1. Thus, it would be in the interest of the medical community to find an easy

2

laboratory finding, such as a serum level, to track the progression of PD before symptoms
manifest.
Recent research has suggested that homocysteine, though the mechanism in PD is not
wholly understood, may be a reliable predictor of cognitive decline. Homocysteine is a nonprotein sulfur containing amino acid that is naturally occurring via metabolism of methionine,
an essential amino acid1. Elevated serum homocysteine levels, hyperhomocysteinemia, can be
caused by deficiencies in folate and vitamin B6 or B12 because of their direct effect in the
biochemical pathway of homocysteine. Hyperhomocysteinemia has also been observed in
patients with renal failure, atherosclerotic and thrombotic vascular disease2. Most notably, high
levels of serum homocysteine, due to its possible neurotoxic effects, has been linked to
Alzheimer’s disease. Homocysteine has agonistic effects on the glutamate binding site of the
NMDA receptor, stimulating the receptors, causing an excitotoxic response2. Homocysteine
disrupts the DNA methylation cycle inducing DNA damage, cell death, and alterations in gene
expression, which can trigger apoptosis and neuronal dysfunction2. Though it is not well
understood, hyperhomocysteinemia’s neurotoxic effects may be linked to the cognitive decline
seen in PD.
Historically, Levodopa (L-dopa) is associated with causing hyperhomocysteinemia. The
suggestion of using hyperhomocysteinemia as a biomarker predicting cognitive decline could
alter the recommendations for treating PD with L-dopa3. The goal of this research is to analyze
for an in situ relationship between homocysteine serum levels and cognitive decline in PD,
independent of L-dopa. The three research articles test serum homocysteine levels and
cognitive decline in patients with PD to assess for an association. The implications of this
relationship could shape the clinical course and treatment of PD.
PICO:
P (Population) → Patients with diagnosis of Parkinson’s Disease (PD)
I (Intervention) → Elevated serum homocysteine levels
C (Comparison) → Lack of current biomarkers
O (Outcomes) → Predicting cognitive decline in PD
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Clinical Question:
Can hyperhomocysteinemia be linked as a causative agent in the progression of cognitive
decline in PD?
Methods:
A systematic literature search was conducted using Google Scholar and PubMed for
articles that reviewed the relationship between serum homocysteine levels and cognitive
decline in PD (see Figure 1). The following keywords were used: Parkinson’s disease,
homocysteine, Parkinson’s progression, and homocysteine levels. Two investigators reviewed
the articles independently and uncertainties were resolved through discussion. Initial screening
criteria excluded articles that were in non-English, non-human, prior to 2016, meta-analyses,
review articles, or full-text articles not available.
Eligibility criteria for study inclusion consisted of: 1) studies evaluating the possible
relationship between homocysteine and cognitive decline in PD patients. Studies that had no
relevant outcomes or had non-Parkinson’s controls were excluded; 2) studies evaluating PD
that used medications as a variable for stratification. Many studies have shown that L-dopa can
increase levels of homocysteine, so this would
be a confounding variable if stratified; 3)
studies with sufficient results with serum
homocysteine and neurocognitive testing.
The quality of the studies were
assessed by the two investigators based on the
sample size, homocysteine measurement, and
cognitive measurement. The final articles were
chosen based on their similarities and the
inclusion/exclusion criteria listed above. No
statistical analysis has been done thus

Figure 1: PRISMA flow diagram depicting the literature review
resulting in the three studies evaluated.
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Results:

Study Comparison
Title & Author

Homocysteine and Cognitive
Function in Parkinson’s Disease,
4
Licking et al.

Vitamin B12 and Homocysteine
Levels Predict Different
Outcomes in Early Parkinson's
5
Disease, Christine et al.

Elevated Serum Homocysteine
Levels Have Differential GenderSpecific Associations with Motor
and Cognitive States in
Parkinson’s Disease, Bakeberg et
6
al.

Year Published

2017

2018

2019

Sample Size

294

680 (456 follow up)

205

Journal

Parkinsonism & Related
Disorders

Movement Disorders

Parkinson’s Disease

Cognitive Measurement

Neurocognitive testing of
memory, visuospatial, executive
functioning, and language

UPDRS, ambulatory capacity
score (sum of UPDRS items 1315, 29&30), and MMSE,
calculated as annualized rates of
change

MDS-UPDRS III and H&Y scale
(physical),
Clinical psychologist and
Neuropsychological
assessments, and
Addenbrooke’s cognitive
function

Homocysteine
Measurement

Homocysteine chromatography,
Serum

Fasting total homocysteine
(tHcy), Serum

Fasting total homocysteine
(tHcy), Serum collected prior to
clinical or psychological
assessments

Elevated Homocysteine
Level Cut off

14 mol/L

15 mol/L

N/A

Outcomes

Elevated homocysteine was
linked with verbal memory
function and semantic fluency
memory, but an overall causal
relationship between
homocysteine and cognitive
function was unclear.

Elevated homocysteine
predicted greater cognitive
decline with decreased MMSE
scores.

Elevated serum homocysteine
levels are associated with a
greater motor impairment in
males with Parkinson’s disease
and poorer cognitive
performance in females with
Parkinson’s disease.

Table 1: Table comparing the demographics of three articles

4,5,6

analyzed in this review.

Study One: Homocysteine and Cognitive Function in Parkinson’s Disease, Licking, et al.4
Objective: This 2017 study investigated the hypothesis that elevated homocysteine levels are
related to a decline in cognitive function in those with Parkinson’s Disease.
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Study Design: 294 patients diagnosed with idiopathic PD, some on treatment and some
without, diagnosed via the United Kingdom Parkinson’s Society Brain Bank (see Table 2), from
the Pacific Northwest Udall Center (PANUC) were given a battery of neurocognitive testing and
had their homocysteine levels measured 4,7. Neurocognitive testing included tests for memory,
executive function, language, and visuospatial function4. After this testing, a diagnosis was
given via consensus conference, either as “no impairment”, “mild cognitive impairment”, or
“dementia”, based on the Movement Disorder Society’s recommendations4. The consensus
conference included neuropsychologists and neurologists that evaluated the patients
holistically, including their testing scores, previous history, and Clinical Dementia Rating. There
were several follow-ups with neurocognitive testing and serum testing from 2010 to 2012.
With each visit, plasma was collected via phlebotomy and frozen until testing. The
plasma was tested via chromatography to assess for homocysteine levels. Elevated levels of
homocysteine were considered if the levels were greater than 14 mol/L4.
The study used least squares, a form of regression analysis to assess the relationship
between cognitive function and hyperhomocysteinemia. Confounding variables, such as age,
gender, Hoehn & Yahr stage, MDS-UPDRS-III score, years of education, and the presence of
APOE4 allele, were corrected to try to control a fraction of the variation between subjects4.

Inclusion Criteria

Exclusion Criteria

Patients with the Pacific Northwest Udall Center that
were diagnosed with idiopathic PD based on United
Kingdom’s Parkinson’s Disease Society Brain Bank
7
(UKBB) criteria .

Failure to meet UKBB criteria for idiopathic PD or
history of neurological disorder than could affect
cognition, like large vessel stroke or severe traumatic
brain injury.

Table 2: Inclusion and exclusion criteria of subjects used in Licking, et al.

Study Result: The overall result of the study was that elevated plasma homocysteine is related
to some elements of cognitive decline, but has an overall unclear effect on cognition. Initially, it
was found that hyperhomocysteinemia was associated with many aspects of cognitive decline
(as seen in table 2). However, once confounding variables were corrected for, such as age and
gender, the association was diminished, thus, making the relationship unclear.
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After correction for confounding variables, hyperhomocysteinemia was still inversely
related to verbal memory function and semantic verbal fluency. Verbal memory function
included delayed recall and immediate recall. These results were statistically significant after
mediation with adjusted p values of less than .004, and .049, respectively4. It was also noted
that with each follow-up a trend was seen where elevated homocysteine contributed to
decrease in scores for the aforementioned neurocognitive subjects, immediate recall, delayed
recall, and semantic verbal fluency. There was statistical significance in these findings with p
values of .012, ,009, and .004, respectively4.
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Table 3. Cognitive outcomes in normal versus elevated homocysteine from the results of Licking, et al.

Critique: Positives of this study include a larger sample size of 294 with fairly specific inclusion
criteria (see table 4). This study was well rounded in that it corrected for several confounding
variables, giving validity to its results. A weakness lies in that there was no way to truly prove a
causal relationship, as there are believed to be several other factors that lead to cognitive
decline in PD. Another weakness of this study is that the study did not have exclusion criteria
for treatment. Treatments, like L-dopa, are notoriously known for altering homocysteine levels,
as well as improving the cognition of those with PD. Thus, medications are a huge confounding
variable within this study.
Study Two: Vitamin B12 and Homocysteine Levels Predict Different Outcomes in Early
Parkinson’s Disease. Christine, et al.5
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Objective: The objective of this large study was to determine the prevalence of low B12 levels
and its metabolites, such as high homocysteine, high methylmalonic acid, and low
holotranscobalamin, in Parkinson’s disease, and if those levels coincided with clinical
progression.
Study Design: 680 baseline and 456 follow-up untreated PD patients from a large study called
DATATOP, Deprenyl and Tocopherol Antioxidative Therapy Of Parkinsonism, were tested for an
association between B12, and its metabolites, and clinical progression of PD. DATATOP was a
double-blind randomized control trial performed from 1987 to 1998 where untreated PD
subjects (see table 4) received one of the four of the following treatments: deprenyl (10 mg/d)
and α-tocopherol-placebo; α-tocopherol (2,000 IU/D) and deprenyl-placebo; active deprenyl
and active α-tocopherol; or double placebo5. Baseline Serum B12, homocysteine levels,
methylmalonic acid, and holotranscobalamin were collected through phlebotomy, transfused,
and then frozen. These B12 levels were repeated every 3 months from 9-24 months if they
subjects remained enrolled. More than 15 mol/L was considered moderately elevated in this
study.
Every 3 months, up to 24 months, PD patients were assessed for clinical progression
through both physical and mental testing, including a baseline value. The cognitive function
was assessed via the mini mental status exam (MMSE), Symbol digit modalities test, Selective
Reminding test, and New Dot test. The cognitive decline was measured as a percent in
response to their scores on the their baseline cognitive testing. The physical progression,
though less important to this review, was measured via UPDRS, the unified Parkinson’s Disease
Rating Scale.

Inclusion Criteria

Exclusion Criteria

Subjects diagnosed with early PD without treatment.

Subjects on treatment for PD, severe PD, tremor, or
diagnosed dementia (MMSE score less than or equal to
22).

Table 4: Inclusion and exclusion criteria of subjects used in Christine, et al.
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Study Result: The overall results of this study, in regards to homocysteine, reported that worse
baseline MMSE were seen with elevated baseline homocysteine, as well as worsening MMSE to
follow-up in those with an elevated baseline homocysteine. 7% of the subjects had an elevated
homocysteine at baseline and those subjects had an average decline in MMSE exam of 1.96
points (see figure 2) . Subjects without that baseline elevation saw an increase in MMSE by
0.06 points ( see figure 2). These results were statistically significant with a p value of .003 and
.001, respectively5. The researchers felt strongly that an elevated baseline homocysteine level
was a predictor for worsening cognitive decline, rather than an elevation overtime. However,
homocysteine levels decreased throughout the study due to treatment, so the relationship is
unclear.

Figure 2: Line graph depicting a comparison in the change in Mini Mental Status Exam (MSSE) score from baseline
to follow-up in those with elevated and normal homocysteine serum levels at baseline from Christine, et al.

Critique. There are several positives within this study. One, is the large sample size at 680
baseline and 456 follow-up subjects. This large sample size gives the study more validity. The
research study was very specific in including only patients without treatment initially and
correcting for various confounding variables during statistical analysis, such as age and gender.
There are also several negatives in this study. This research was sponsored by the
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Michael J. Fox Foundation, potentially introducing some bias to the study as it is a heavily
publicized foundation. Also, there is no explanation as to why there were 224 patients loss to
follow-up. If the patients lost to follow-up were at a worse disease state, this could introduce
bias into the results by skewing them towards a less severe result.
Study Three: Elevated Serum Homocysteine Levels Have Differential Gender-Specific
Associations with Motor and Cognitive States in Parkinson’s Disease, Bakeberg et al.6
Objective: This study aimed to investigate elevated serum homocysteine levels, with serum
folate and vitamin B12 levels as controls, and its association with motor and cognitive symptom
progression in a cohort of PD patients, with the consideration of gender-specific differences.
Study Design: 205 home-based patients with Parkinson’s Disease (128 males and 77 females)
and 78 (31 males and 47 females) aged-matched healthy controls were sequentially recruited
from Movement Disorders Clinics Perth, Australia, Melbourne, Victoria, and Sydney, New South
Wales, between 2012 and 2015 (refer to table 5). All PD patients were diagnosed in accordance
with the UK Brain Bank criteria for idiopathic PD.
All PD medications were converted to a total levodopa equivalent dose (LED). Motor
symptoms were evaluated in the “ON” state using the MDS-UPDRS and H&Y Scale. In addition,
each participant was evaluated by a clinical psychologist and completed a panel of
neuropsychological assessments using the revised Addenbrooke's Cognitive Examination (ACER).
Fasted patient and healthy volunteer control blood samples were collected prior to
clinical or psychological assessments, from the medial cubital vein and stored in a standard
vacutainer. Serum homocysteine, vitamin B12, and folate were recorded for analysis in this
study.
Data were analysed using IBM-SPSS. Where appropriate, univariate regression analysis
or Mann–Whitney U-test was performed to identify differences between patient and control
serum markers. Generalised linear models (GLM) were used to investigate outcome measures,
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such as motor severity and cognitive score, with serum Hcy as an independent variable.
Variables included in the GLMs were as follows: age at assessment, LED, DBS history, and
disease duration. A significant nominal p value of ≤ 0.05 was employed.

Inclusion Criteria

Exclusion Criteria

Home-based patients diagnosed with idiopathic PD
based on UKBB criteria, recruited from movement
disorder clinic from 2012 to 2015.

Failure to meet UKBB criteria for idiopathic PD, which
was conducted by a movement disorder neurologist.

Table 5: Inclusion and exclusion criteria of subjects used in Bakeberg, et al.

Study Result: Mean comparisons revealed significant differences in serum homocysteine in
males and females with PD. In male patients, a significant positive correlation between
homocysteine levels and MDS-UPDRS III (rs = 0.319, p < 0.001) was observed. In contrast, there
was no significant association between homocysteine levels and MDS-UPDRS III scores in
females. Conversely, in female patients, homocysteine levels were significantly inversely
correlated with cognitive scores, as indicated by the ACE-R total score (rs = −0.449, p < 0.001),
whereas there was no association between homocysteine levels and cognitive scores in male
PD patients.
Critique: There are many positives within this study, such as having controls to compare
normal homocysteine levels and the gender-specific differences. This study also included
patients without treatment of Levodopa and correlated their symptoms with levodopa
equivalent doses. Although home-based PD patients were recruited to overcome selection bias,
the study did not include patients with more advanced PD who were no longer independent.
This was a cross-sectional study, so the levels of homocysteine over the course of the disease
were not measured. Further, as the ACE-R does not include tests of executive function.
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Discussion:
Parkinson’s disease (PD) is a chronic and progressive neurological disease that is
characterised by the onset of an array of motor and nonmotor signs and symptoms. The motor
symptoms include resting tremor, rigidity, akinesia, bradykinesia, and postural instability, and
the non-motor symptoms include cognitive impairment, apathy, emotional disturbance, and
sleep disturbance3. Little is known about the specific pathological mechanism behind the death
of neurons in PD, so factors that can predict these varying outcomes and potential diagnostic
biomarkers of this degenerative disease require exploration.
There are three main hypotheses that are being explored in this paper: 1)
Homocysteine is an indirect neurotoxin that can cause some of the neurocognitive decline in
PD; 2) If the first hypothesis is true and there is a causative effect between
hyperhomocysteinemia and PD, then decreasing the levels of serum homocysteine during the
treatment of PD can decrease some of the cognitive decline; 3) If the first statement is false and
there is no causative effect between hyperhomocysteinemia and PD, then an alternative reason
must be considered and serum homocysteine can possibly be used as a biomarker to predict
the progression of cognitive decline or even the rate of decline in PD.
There are many theories of how homocysteine may be neurotoxic. For one, there is
some evidence that homocysteine has an agonistic relationship the glutamate binding site on
the NMDA receptor, causing excitotoxic reactions within neurons1. Also, studies show that
elevated homocysteine levels are associated with an increase in the dopaminergic neurotoxin,
1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine (MPTP)1. Lastly, there is evidence that
homocysteine increases cellular oxidative stress1. Several in vitro studies have found this
toxicity occurs in various types of neurons, including cortical, postnatal cerebellar granule,
cerebellar Purkinje, dorsal root ganglions, hippocampal, and trigeminal sensory1. The studies
that were analyzed in this paper were able to demonstrate correlations between
hyperhomocysteinemia and cognitive decline in PD but fall short of demonstrating a causal
relationship.
Several studies researching the potential relationship between serum homocysteine and
PD progression exist. The three studies analyzed in this paper include two main variables in
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their research: one, neurocognitive testing and two, serum homocysteine collected the day of
mental status testing 4,5,6. These papers also included discussions that statistically analyzed the
relationship between serum homocysteine and cognitive function4,5,6. Two, Bakeberg, et al.,
and Christine, et al., also included data and analysis on serum homocysteine levels and the
progression of physical symptoms in PD5,6. Bakeberg et al, Christine,et al., and Licking, et al,
found inversely proportional relationships between serum homocysteine levels and some
aspects of cognition in specific populations in PD patients. However, there are many
confounding variables, such as age, gender, and dementia, that can influence the levels of
serum homocysteine, making it difficult to analyze as a variable in PD. In this research, an
overarching theme seen was that patients with hyperhomocysteinemia were generally older
with a longer duration of disease. These two variables, age and length of disease, are known to
contribute to the cognitive decline sequelae seen in PD. Thus, it is difficult to isolate
homocysteine in these studies as the cause of the cognitive decline, when these subjects also
have many risk factors for cognitive decline in PD.
The authors of the third study believe that their findings of a gender effect may help to
explain previous discrepancies in the literature surrounding the utility of homocysteine as a
biomarker in PD6. They also controlled for the confounding variable of age by comparing their
serum homocysteine levels to age-matched healthy controls. This demonstrates that research is
heading in the right direction and it warrants further consideration in future larger studies of
PD. These future studies may tease out how serum homocysteine can be helpful in the
treatment of PD.
Conclusion:
If futures studies were able to better support the theory of the inverse relationship
between homocysteine and cognitive decline in PD, treatment and monitoring of the disease
could be changed and potentially improved. The implications from this potential relationship
are of the utmost importance. For one, L-dopa, a mainstay pharmacologic treatment for PD, is
known to elevate homocysteine levels3. If the inverse relationship is true, L-dopa could be
unknowingly increasing cognitive decline in PD patients. This could propagate a shift in
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pharmacologic treatment for PD management. Also, with the current state of PD monitoring,
patients are left with an unpredictable prognosis and unknown disease status. A more concrete
serum level, like homocysteine, would be advantageous in allowing patients and their
caretakers to prepare for cognitive decline and potentially begin preventative treatment earlier.
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